NEW YORK (GenomeWeb News) – NanoString Technologies said after the close of the market Tuesday that several US clinical laboratories will adopt the company's breast cancer assay starting in the first quarter of 2014.
Registering provides access to this and other free content.
Already have an account?Login Now.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.